Início › Câncer de Rim (Carcinoma de Células Renais) › Texas

Ensaios clínicos de Câncer de Rim (Carcinoma de Células Renais) em Texas

56 estudos para Câncer de Rim (Carcinoma de Células Renais) estão buscando participantes em locais em Texas.

Cidades em Texas

Texto oficial do estudo (Inglês)

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Research Site, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT05536141

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NEO-811 Dallas Site, Dallas
NEO-811 Houston Site, Houston

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 5 de out. de 2026 · NCT07300241

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NEXT Austin, Austin
START Center for Clinical Research, Fort Worth
University of Texas MD Anderson Cancer Center, Houston
e mais 1

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06270706

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Texas Oncology, Dallas
University of Texas Southwestern Medical Center, Dallas
University Medical Center & Texas Tech Health Science Center, Lubbock

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06234605

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

The Don and Sybil Harrington Cancer Center, Amarillo
UT MD Anderson Cancer Center, Houston
Audie L Murphy VA Hospital, San Antonio

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #46, Austin
Exelixis Clinical Site #89, Dallas
Exelixis Clinical Site #73, Irving
e mais 2

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

University of Texas - MD Anderson Cancer Center, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05287945

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

UT Southwestern Simmons Cancer Center - RedBird, Dallas
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
e mais 1

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT03866382

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

UT MD Anderson Cancer Center, Houston

RecrutandoFase 2

Idades 12 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT04981509

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

The University of Texas MD Anderson Cancer Center, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07594106

DESTINY-PANTUMOUR04

Research Site, Dallas

RecrutandoEstudo observacional

Idades de 18 a 130 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07124000

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Baylor, Scott and White Research Institute, Dallas

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06047379

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Texas Oncology (Balcones) - SCRI, Austin
MD Anderson Cancer Center, Houston
START South Texas Accelerated Research Therapeutics, San Antonio

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT05267626

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

M D Anderson Cancer Center, Houston

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT05048212

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Parkland Memorial Hospital, Dallas
UT Southwestern Simmons Cancer Center - RedBird, Dallas
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
e mais 3

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT05327686

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Texas Oncology - Central South, Austin
Texas Oncology - Central South, Austin
Texas Oncology - Central South, Austin
e mais 26

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07227415

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

University of Texas Southwestern Medical Center, Dallas

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT05319015

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

The University of Texas MD Anderson Cancer Center, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT04969315

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Md Anderson Cancer Center, Houston

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT07195916

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

UT Southwestern Medical Center, Dallas
DHR Health Advance Care Center, Edinburg
The Center for Cancer and Blood Disorders, Forth Worth
e mais 1

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Mary Crowley Cancer Research, Dallas

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06750185

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

The Don and Sybil Harrington Cancer Center, Amarillo
Houston Methodist San Jacinto Hospital, Baytown
Houston Methodist Cypress Hospital, Cypress
e mais 13

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06661720

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

START San Antonio, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 27 de ago. de 2026 · NCT06582017

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

MD Anderson Cancer Center, Houston

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT06940518

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

The University of Texas M. D. Anderson Cancer Center, Houston

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 20 de ago. de 2026 · NCT07187778

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Research Site, Houston
Research Site, San Antonio

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT07115043

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

University of Texas, Southwestern Medical Center, Dallas

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT05361720

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

NEXT Oncology, Austin, Austin
NEXT Oncology, San Antonio, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT06966024

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Houston Methodist Hospital, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT04895709

A Study of MGC026 in Participants With Advanced Solid Tumors

The University of Texas MD Anderson Cancer Center, Houston
University of Texas Health Science Center at Houston, Houston

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT06242470

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

START San Antonio, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT07195682

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

The University of Texas M. D. Anderson Cancer Center, Houston

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 11 de ago. de 2026 · NCT07187869

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

Clinical Trial Site, San Antonio

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT07749586

IDOV-Immune for Advanced Solid Tumors

MD Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics, San Antonio

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06910657

PET/MR for Characterization of Renal Masses (RMs)

University of Texas Southwestern Medical Center, Dallas
The University of Texas MD Anderson Cancer Center, Houston

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT06076538

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

MD Anderson Cancer Center, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT05663710

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

The University of Texas Health Science Center at Tyler, Tyler

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 29 de jul. de 2026 · NCT04198766

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

UT MD Anderson, Houston

RecrutandoFase 1

Idades de 18 a 70 · Todos os sexos · Atualizado em 29 de jul. de 2026 · NCT07564232

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

M D Anderson Cancer Center, Houston

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 16 de jul. de 2026 · NCT05092373

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

MD Anderson Cancer Center, Houston

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 9 de jul. de 2026 · NCT03972657

Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.